NASDAQ:EVLOEvelo Biosciences Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Evelo Biosciences Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $4.40 -0.10 (-2.22 %) (As of 07/10/2020 04:00 PM ET) Add Compare Share Today's Range$4.30Now: $4.40▼$4.5250-Day Range$3.59MA: $4.35▼$5.1652-Week Range$3.01Now: $4.40▼$9.27Volume58,700 shsAverage Volume106,023 shsMarket Capitalization$142.27 millionP/E RatioN/ADividend YieldN/ABeta1 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Evelo Biosciences, Inc., a biotechnology company, focuses on the development of monocolonal microbials for the treatment of inflammatory diseases and cancer. It is involved in developing EDP1066 and EDP1815, which are in Phase 1b placebo-controlled dose-escalating safety and tolerability clinical study for the treatment of atopic dermatitis, asthma, psoriatic arthritis, rheumatoid arthritis, and inflammatory bowel diseases. The company is also involved in developing EDP150, a monoclonal microbial candidate, which is in Phase 1/2 clinical study for the treatment of colorectal cancer, triple-negative breast cancer, and melanoma, as well as patients who have relapsed on prior PD-1/L1 inhibitor treatment across multiple tumor types. Evelo Biosciences, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.Read More Beat the Market (BTM) Rank™ 3.2 Analyst's Opinion Consensus RatingEvelo Biosciences has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 2 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $10.33, Evelo Biosciences has a potential upside of 134.8% from its current price of $4.40.Amount of Analyst CoverageEvelo Biosciences has only been the subject of 3 research reports in the past 90 days. Previous Next 2.4 Community Rank Outperform VotesEvelo Biosciences has received 142 “outperform” votes. (Add your “outperform” vote.)Underperform VotesEvelo Biosciences has received 154 “underperform” votes. (Add your “underperform” vote.)Community SentimentEvelo Biosciences has received 52.03% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Evelo Biosciences and other stocks. Vote “Outperform” if you believe EVLO will outperform the S&P 500 over the long term. Vote “Underperform” if you believe EVLO will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldEvelo Biosciences does not currently pay a dividend.Dividend GrowthEvelo Biosciences does not have a long track record of dividend growth. Previous Next 5.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Evelo Biosciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $17,499,998.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders59.10% of the stock of Evelo Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions85.24% of the stock of Evelo Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Evelo Biosciences are expected to grow in the coming year, from ($2.45) to ($1.88) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Evelo Biosciences is -1.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Evelo Biosciences is -1.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEvelo Biosciences has a P/B Ratio of 2.34. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.2Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 5.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™2.25 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:EVLO Previous Symbol CUSIPN/A CIK1694665 Webwww.evelobio.com Phone617-577-0300Debt Debt-to-Equity Ratio0.50 Current Ratio4.89 Quick Ratio4.89Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.88 per share Price / Book2.34Profitability EPS (Most Recent Fiscal Year)($2.67) Net Income$-85,470,000.00 Net MarginsN/A Return on Equity-125.94% Return on Assets-85.77%Miscellaneous Employees75 Outstanding Shares32,333,000Market Cap$142.27 million Next Earnings Date8/4/2020 (Estimated) OptionableNot Optionable NASDAQ:EVLO Rates by TradingView Receive EVLO News and Ratings via Email Sign-up to receive the latest news and ratings for EVLO and its competitors with MarketBeat's FREE daily newsletter. Evelo Biosciences (NASDAQ:EVLO) Frequently Asked Questions How has Evelo Biosciences' stock been impacted by COVID-19 (Coronavirus)? Evelo Biosciences' stock was trading at $4.37 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, EVLO stock has increased by 0.7% and is now trading at $4.40. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Evelo Biosciences? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evelo Biosciences in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Evelo Biosciences. When is Evelo Biosciences' next earnings date? Evelo Biosciences is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Evelo Biosciences. How were Evelo Biosciences' earnings last quarter? Evelo Biosciences Inc (NASDAQ:EVLO) issued its quarterly earnings data on Monday, May, 11th. The company reported ($0.71) EPS for the quarter, beating analysts' consensus estimates of ($0.73) by $0.02. View Evelo Biosciences' earnings history. What price target have analysts set for EVLO? 5 brokers have issued 12-month price targets for Evelo Biosciences' stock. Their forecasts range from $6.00 to $17.00. On average, they expect Evelo Biosciences' stock price to reach $10.33 in the next twelve months. This suggests a possible upside of 134.8% from the stock's current price. View analysts' price targets for Evelo Biosciences. Has Evelo Biosciences been receiving favorable news coverage? Media stories about EVLO stock have been trending negative recently, InfoTrie Sentiment reports. The research group identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Evelo Biosciences earned a news sentiment score of -2.4 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the near term. View the latest news about Evelo Biosciences. Are investors shorting Evelo Biosciences? Evelo Biosciences saw a increase in short interest in the month of June. As of June 30th, there was short interest totaling 1,810,000 shares, an increase of 8.4% from the June 15th total of 1,670,000 shares. Based on an average daily trading volume, of 81,100 shares, the days-to-cover ratio is presently 22.3 days. Currently, 15.6% of the company's stock are short sold. View Evelo Biosciences' Current Options Chain. Who are some of Evelo Biosciences' key competitors? Some companies that are related to Evelo Biosciences include Atreca (BCEL), Collegium Pharmaceutical (COLL), Kala Pharmaceuticals (KALA), Legend Biotech (CALT), Athersys (ATHX), Corbus Pharmaceuticals (CRBP), Syndax Pharmaceuticals (SNDX), Syros Pharmaceuticals (SYRS), Crinetics Pharmaceuticals (CRNX), Catalyst Pharmaceuticals (CPRX), Urogen Pharma (URGN), NextCure (NXTC), Protagonist Therapeutics (PTGX), Clovis Oncology (CLVS) and Viking Therapeutics (VKTX). View all competitors. What other stocks do shareholders of Evelo Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Evelo Biosciences investors own include AbbVie (ABBV), Aldeyra Therapeutics (ALDX), Allena Pharmaceuticals (ALNA), Gilead Sciences (GILD), Obseva (OBSV), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX), Arbutus Biopharma (ABUS), Apellis Pharmaceuticals (APLS) and Ardelyx (ARDX). Who are Evelo Biosciences' key executives? Evelo Biosciences' management team includes the following people: Dr. Noubar B. Afeyan Ph.D., Co-founder & Chairman (Age 56)Dr. Balkrishan Gill, Pres, CEO & Director (Age 54)Dr. Mark Bodmer, Chief Scientific Officer and Pres of R&D (Age 61)Dr. Duncan McHale M.D., Ph.D., Chief Medical Officer (Age 52)Mr. Jonathan Poole, CFO & Treasurer (Age 44) When did Evelo Biosciences IPO? (EVLO) raised $85 million in an IPO on Wednesday, May 9th 2018. The company issued 5,300,000 shares at $15.00-$17.00 per share. Morgan Stanley, Cowen and BMO Capital Markets served as the underwriters for the IPO and JMP Securities was co-manager. What is Evelo Biosciences' stock symbol? Evelo Biosciences trades on the NASDAQ under the ticker symbol "EVLO." How do I buy shares of Evelo Biosciences? Shares of EVLO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Evelo Biosciences' stock price today? One share of EVLO stock can currently be purchased for approximately $4.40. How big of a company is Evelo Biosciences? Evelo Biosciences has a market capitalization of $142.27 million. The company earns $-85,470,000.00 in net income (profit) each year or ($2.67) on an earnings per share basis. Evelo Biosciences employs 75 workers across the globe. What is Evelo Biosciences' official website? The official website for Evelo Biosciences is www.evelobio.com. How can I contact Evelo Biosciences? Evelo Biosciences' mailing address is 620 Memorial Drive Suite 500 West, Cambridge MA, 02139. The company can be reached via phone at 617-577-0300 or via email at [email protected] This page was last updated on 7/10/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
